Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses HROW in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named HROW in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Baum | $754,910 | $0 | $22,294,873 | $0 | $542,491 | $0 | $14,000 | $23,606,274 |
| Chief Executive Officer and Chairman of the Board of Directors | ||||||||
| Andrew Boll | 505,259 | 0 | 10,169,924 | 0 | 258,258 | 0 | 14,000 | 10,947,441 |
| President, Chief Financial Officer and Corporate Secretary | ||||||||
| Amir Shojaei | 441,346 | 0 | 0 | 670,569 | 225,000 | 0 | 5,712 | 1,342,627 |
| Chief Scientific Officer | ||||||||
| Francis Mullery | 129,808 | 0 | 0 | 1,054,624 | 53,260 | 0 | 0 | 1,237,692 |
| President and Chief Executive Officer, ImprimisRx Division | ||||||||
| John Saharek | 475,614 | 0 | 0 | 0 | 237,807 | 0 | 14,000 | 727,421 |
| Former President and Chief Executive Officer, ImprimisRx Division | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mark Baum | $23,606,274 | — | — | — |
| Andrew Boll | 10,947,441 | — | — | — |
| Amir Shojaei | 1,342,627 | — | — | — |
| Francis Mullery | 1,237,692 | — | — | — |
| John Saharek | 727,421 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Boll | PRESIDENT AND CFO | 2026-05-14 | A | 3,500 | $30 | $104,650 | Common | Form 4 ↗ |
| Mark L. Baum | Director | 2026-05-14 | A | 10,000 | 30 | 302,000 | Common | Form 4 ↗ |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 2026-05-15 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren P. Silvernail | Director | 2026-05-18 | A | 1,000 | 31 | 31,000 | Common | Form 4 ↗ |
| Adrienne L. Graves | Director | 2026-05-18 | A | 1,000 | 31 | 31,070 | Common | Form 4 ↗ |
| Lauren P. Silvernail | Director | 2026-06-18 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Perry J. Sternberg | Director | 2026-06-18 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adrienne L. Graves | Director | 2026-06-18 | A | 5,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Amir Shojaei | OPTION | 2025-01-06 | — | — | 30,000 | — | $670,569 |
| Mark Baum | RSU | 2025-07-01 | — | — | 889,500 | — | 22,294,873 |
| Andrew Boll | RSU | 2025-07-01 | — | — | 405,750 | — | 10,169,924 |
| Francis Mullery | OPTION | 2025-09-30 | — | — | 33,000 | — | 1,054,624 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Amir Shojaei | $0 | $0 | $670,569 | 0.0% |
| Mark Baum | 22,294,873 | 0 | 0 | 0.0% |
| Andrew Boll | 10,169,924 | 0 | 0 | 0.0% |
| Francis Mullery | 0 | 0 | 1,054,624 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew Boll | PSU | 258,258 | — | $464,864 |
| Francis Mullery | Option | 33,000 | 48.18 | — |
| Amir Shojaei | Option | 30,000 | 35.96 | — |
| Amir Shojaei | PSU | 225,000 | — | 405,000 |
| Francis Mullery | PSU | 52,260 | — | 94,068 |
| Mark Baum | PSU | 889,500 | — | 1,601,100 |
| John Saharek | PSU | 237,807 | — | 428,053 |
| Mark Baum | PSU | 542,491 | — | 976,484 |
| Andrew Boll | PSU | 405,750 | — | 730,350 |
The Compensation Committee believes that executive compensation should be directly linked both to continuous improvements in corporate performance (pay for performance) and the achievement of objectives that are expected to increase stockholder value.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer, Inc. |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 18,065,856 | 2,395,240 | 502,679 | 88.29% | Passed |
| 2025 | 2025-06-18 | 22,496,427 | 971,206 | 448,777 | 95.86% | Passed |
| 2024 | 2024-06-14 | 14,877,198 | 1,709,038 | 133,736 | 89.7% | Passed |
| 2023 | 2023-06-21 | 19,733,427 | 849,799 | 288,213 | 95.87% | Passed |
| 2022 | 2022-06-09 | 13,569,789 | 284,580 | 40,157 | 97.95% | Passed |
| 2021 | 2021-06-03 | 14,781,072 | 600,632 | 583,327 | 96.1% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-18 | 88.29%a |
| 2025 | 2025-06-18 | 95.86%b |
| 2024 | 2024-06-14 | 89.7%c |
a. Approved under the standard stated in the filing — “Because directors are elected by a plurality of the votes cast, abstentions and broker non-votes will not be counted in determining which nominees receive the largest number of votes cast and, therefore, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “Because directors are elected by a plurality of the votes cast, abstentions and broker non-votes will not be counted in determining which nominees receive the largest number of votes cast and, therefore, will have no effect on the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “Because directors are elected by a plurality of the votes cast, abstentions and broker non-votes will not be counted in determining which nominees receive the largest number of votes cast and, therefore, will have no effect on the outcome of the vote on this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 263 : 1 |
|---|---|
| CEO total compensation | $23,606,274 |
| Median employee compensation | $89,719 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Perry J. SternbergIndependent · Lead Independent Director · Audit · Compensation · Nominating/Governance | $102,500 | $225,014 | $0 | $0 | $0 | $327,514 |
| Adrienne L. GravesIndependent · Audit · Compensation (Chair) · Nominating/Governance (Chair) | 83,750 | 225,014 | 0 | 0 | 0 | 308,764 |
| Lauren P. SilvernailIndependent · Audit (Chair) · Compensation · Nominating/Governance | 82,500 | 225,014 | 0 | 0 | 0 | 307,514 |
| Martin A. MakaryIndependent · Audit · Compensation · Nominating and Corporate Governance · Not standing for re-election · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
| Mark L. BaumEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $268,750 |
| Equity awards (grant-date value) | $675,042 |
| All other compensation | $0 |
| Total cost of the board | $943,792 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Harrow names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Harrow.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Harrow | 2025 | Mark Baum | $754,910 | $22,294,873 | $0 | $542,491 | $23,606,274 |
| 2 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 3 | ANI Pharmaceuticals | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 4 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 5 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 6 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 7 | STAAR Surgical | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 8 | Tarsus Pharmaceuticals | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 9 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 10 | RxSight | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 11 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 12 | Ironwood Pharmaceuticals | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| — | Eyepoint Pharmaceuticals | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Harrow | 100% | not disclosed | No | Mercer, Inc. |
| Agios Pharmaceuticals | 100% | Options 40 · PSU 40 · RSU 20 | No | Aon |
| ANI Pharmaceuticals | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Arrowhead Pharmaceuticals | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Eyepoint Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| Heron Therapeutics | 100% | Options 67 · RSU 33 | not disclosed | Compensia, Inc. |
| Ironwood Pharmaceuticals | 100% | PSU 50 · RSU 50 | Yes — relative total stockholder return (rTSR) | Alpine Rewards LLC |
| Mirum Pharmaceuticals | 200% | not disclosed | No | Alpine Rewards |
| RxSight | 32.18% | Options 100 | not disclosed | Aon Human Capital Solutions |
| STAAR Surgical | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Tarsus Pharmaceuticals | 108% | Options 50 · RSU 50 | No | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mark Baum | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Summary Compensation Table”. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999 |
| 2 | Section 01, Andrew Boll | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Summary Compensation Table”. As printed: 10,947,441. Filing ↗machine: t87 · r4 · c26 · span 390346–390356 |
| 3 | Section 01, Amir Shojaei | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Summary Compensation Table”. As printed: 1,342,627. Filing ↗machine: t87 · r8 · c26 · span 394722–394731 |
| 4 | Section 01, Francis Mullery | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Summary Compensation Table”. As printed: 1,237,692. Filing ↗machine: t87 · r7 · c26 · span 393586–393595 |
| 5 | Section 01, John Saharek | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Summary Compensation Table”. As printed: 727,421. Filing ↗machine: t87 · r9 · c26 · span 395905–395912 |
| 6 | Section 03, Amir Shojaei OPTION | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t87 · r8 · c14 · span 394313–394320 |
| 7 | Section 03, Mark Baum RSU | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t91 · r2 · c25 · span 413517–413524 |
| 8 | Section 03, Andrew Boll RSU | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t91 · r4 · c25 · span 416837–416844 |
| 9 | Section 03, Francis Mullery OPTION | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t87 · r7 · c14 · span 393180–393189 |
| 10 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “CEO Pay Ratio”. As printed: 263 : 1. Filing ↗machine: t117 · r1 · c3 · span 548949–548955 |
| 11 | Section 08, Perry J. Sternberg | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Director Compensation”. As printed: 327,514. Filing ↗machine: t48 · r3 · c11 · span 243128–243135 |
| 12 | Section 08, Adrienne L. Graves | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Director Compensation”. As printed: 308,764. Filing ↗machine: t48 · r1 · c11 · span 241699–241706 |
| 13 | Section 08, Lauren P. Silvernail | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Director Compensation”. As printed: 307,514. Filing ↗machine: t48 · r2 · c11 · span 242440–242447 |
| 14 | Section 08, Martin A. Makary | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t48 · r4 · c15 · span 243931–243932 |
| 15 | Section 08, Mark L. Baum | DEF 14A | 2026-04-24 | 0001493152-26-018912 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 02, Andrew Boll 2026-05-14 | Form 4 | 2026-05-15 | 0001493152-26-023319 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Mark L. Baum 2026-05-14 | Form 4 | 2026-05-15 | 0001493152-26-023321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Amir Shojaei 2026-05-15 | Form 4 | 2026-05-18 | 0001493152-26-024208 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Lauren P. Silvernail 2026-05-18 | Form 4 | 2026-05-19 | 0001493152-26-024341 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Adrienne L. Graves 2026-05-18 | Form 4 | 2026-05-19 | 0001493152-26-024342 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Lauren P. Silvernail 2026-06-18 | Form 4 | 2026-06-22 | 0001493152-26-029658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Perry J. Sternberg 2026-06-18 | Form 4 | 2026-06-22 | 0001493152-26-029659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Adrienne L. Graves 2026-06-18 | Form 4 | 2026-06-22 | 0001493152-26-029657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 06, 2026 vote | Form 8-K | 2026-06-22 | 0001493152-26-029486 | Item 5.07 · say-on-pay result. As reported: 88.29% (votes for as printed: 18,065,856). Filing ↗ |
| 25 | Section 06, 2025 vote | Form 8-K | 2025-06-20 | 0001641172-25-015665 | Item 5.07 · say-on-pay result. As reported: 95.86% (votes for as printed: 22,496,427). Filing ↗ |
| 26 | Section 06, 2024 vote | Form 8-K | 2024-06-17 | 0001493152-24-024111 | Item 5.07 · say-on-pay result. As reported: 89.7% (votes for as printed: 14,877,198). Filing ↗ |
| 27 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 28 | Section 09b board cost (computed) | Computed | — | computed | Cash 268,750 + equity 675,042 + all other 0 = 943,792, summed across the director compensation table rows.machine: formula: Σ = 943,792 |
| 29 | Harrow (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001493152-26-018912 | CEO total compensation as printed in Harrow's own proxy. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999 |
| 30 | Mirum Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 31 | ANI Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals's own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 32 | Arrowhead Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 33 | Dynavax Technologies, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗ |
| 34 | Ardelyx, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 35 | STAAR Surgical, Section 10b CEO total | DEF 14A | 2026-05-04 | 0000718937-26-000015 | CEO total compensation as printed in STAAR Surgical's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486 |
| 36 | Tarsus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001819790-26-000028 | CEO total compensation as printed in Tarsus Pharmaceuticals's own proxy. As printed: 6,617,979. Filing ↗machine: span 448592–448601 |
| 37 | Agios Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 38 | RxSight, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187240 | CEO total compensation as printed in RxSight's own proxy. As printed: 4,650,661. Filing ↗machine: t20 · r4 · c24 · span 978530–978539 |
| 39 | Heron Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-196306 | CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221 |
| 40 | Ironwood Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191 |
| 41 | Section 10a, RxSight reciprocity | DEF 14A | — | 0001193125-26-187240 | RxSight's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 42 | Section 10a, Dynavax Technologies reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 43 | Section 10a, Arrowhead Pharmaceuticals reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 44 | Section 10a, Ardelyx reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 45 | Section 10a, Agios Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 46 | Section 10a, Mirum Pharmaceuticals reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 47 | Section 10a, Heron Therapeutics reciprocity | DEF 14A | — | 0001193125-26-196306 | Heron Therapeutics names Harrow in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 48 | Section 10a, STAAR Surgical reciprocity | DEF 14A | — | 0000718937-26-000015 | STAAR Surgical's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 49 | Section 10a, ANI Pharmaceuticals reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗ |
| 50 | Section 10a, Tarsus Pharmaceuticals reciprocity | DEF 14A | — | 0001819790-26-000028 | Tarsus Pharmaceuticals names Harrow in its own disclosed peer group (read from its most recent proxy). Filing ↗ |